Cited by 538Lung Cancer Research StudiesCancer-related Molecular PathwaysCancer Cells and Metastasis

Cell of Origin of Small Cell Lung Cancer: Inactivation of Trp53 and Rb1 in Distinct Cell Types of Adult Mouse Lung

Open access
Sutherland, Kate D., Proost, Natalie, Brouns, Inge, Adriaensen, Dirk, Song, Ji-Ying, Berns, Anton·2011·Cancer Cell

Abstract

Small cell lung cancer (SCLC) is one of the most lethal human malignancies. To investigate the cellular origin(s) of this cancer, we assessed the effect of Trp53 and Rb1 inactivation in distinct cell types in the adult lung using adenoviral vectors that target Cre recombinase to Clara, neuroendocrine (NE), and alveolar type 2 (SPC-expressing) cells. Using these cell type-restricted Adeno-Cre viruses, we show that loss of Trp53 and Rb1 can efficiently transform NE and SPC-expressing cells leading to SCLC, albeit SPC-expressing cells at a lesser efficiency. In contrast, Clara cells were largely resistant to transformation. The results indicate that although NE cells serve as the predominant cell of origin of SCLC a subset of SPC-expressing cells are also endowed with this ability.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2011.04.019

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • There is preclinical evidence that type II alveolar cells have the potential to differentiate into SCLC after the targeted disruption of Tp53 and Rb1.

    “In particular, there is preclinical evidence that type II alveolar cells have the potential to differentiate into SCLC after the targeted disruption of Tp53 and Rb1.35”

    From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [35]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 48 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Sutherland, K. D., Proost, N., Brouns, I., Adriaensen, D., Song, J.-Y., & Berns, A.
Affiliations
  • The Netherlands Cancer Institute (NL)
  • University of Antwerp (BE)
Corresponding author
Berns, Anton
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2011-06
Volume
19
Issue
6
Pages
754-764
ISSN
1535-6108 (ISSN-L)
OpenAlex
W1972570571
Cited by
534
References
48
Citations by year
2026: 22 · 2025: 54 · 2024: 41 · 2023: 48 · 2022: 33 · 2021: 50 · 2020: 40 · 2019: 28 · 2018: 37 · 2017: 33 · 2016: 31 · 2015: 33 · 2014: 20 · 2013: 27 · 2012: 21
FWCI
13.24
Type
journal article
Language
en
Open access
Locations
  • Cancer Cell (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Health and Medical Research Council (516781)
  • Fonds De La Recherche Scientifique - FNRS
  • National Institutes of Health
Topics
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
small cell lung cancer, cell of origin, RB1 inactivation, Clara cells, neuroendocrine cells, alveolar type II cells
MeSH terms
Adenoviridae, Animals, Cell Transformation, Neoplastic, Lung, Lung Neoplasms, Tumor Suppressor Protein p53, Retinoblastoma Protein, Integrases, Mice, Neuroendocrine Cells, Small Cell Lung Carcinoma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review